Spots Global Cancer Trial Database for Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

Official Title: A Pilot Study Evaluating the Feasibility of Memantine in Reducing Cognitive Impairment in Pediatric Patients After Radiation Therapy for Central Nervous System Tumors

Study ID: NCT04217694

Conditions

Malignant Central Nervous System Neoplasm

Primary Central Nervous System Neoplasm

Interventions

Cogstate Assessment Battery

Memantine

Memantine Hydrochloride

Study Description

Brief Summary: This early phase I trial studies the feasibility of giving memantine for the reduction of cognitive impairment after radiation therapy in pediatric patients with central nervous system tumors. Memantine may reduce the effects of radiation therapy on memory and thinking.

Detailed Description: PRIMARY OBJECTIVE: I. To evaluate the feasibility of twice daily memantine started before radiation therapy (RT) and one month after RT. SECONDARY OBJECTIVE: I. To evaluate the feasibility of twice daily (BID) memantine started before RT and continued 3 and 6 months after RT. EXPLORATORY OBJECTIVES: I. To evaluate the change in neurocognitive function (NCF) as found by formal neurocognitive testing between baseline and 12 months post-RT. II. To compare the change in NCF between baseline and the end of RT, 3,and 6 months after RT using both neuropsychological testing and the CogState exam. III. To evaluate changes in quantitative volumetric brain imaging using Neuroquant software analysis of magnetic resonance imaging (MRI) imaging before and 12 months after radiation. IV. To correlate cognitive changes detected by CogState composite score and formal neuropsychological testing. V. Disease-free (of primary tumor) and overall survival. OUTLINE: Patients receive memantine orally (PO) BID beginning at the time of study enrollment (no later than 1st day of RT) up to 6 months after completion of standard of care RT in the absence of unacceptable toxicity. Patients also complete CogState cognitive testing at baseline, at completion of RT, and at 3, 6, and 12 months after completion of RT. After completion of study, patients are followed up periodically.